SDC1 and breast cancer: According to our findings, Syndecan-1 silencing in triple-negative MDA-MB-231 breast cancer cells inhibited proinflammatory signaling via downregulation of relevant receptors and ligands (IL-6/IL6-R/CCL20), which was linked to reduced constitutive activation of NFkB and STAT3.